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INTRODUCTION
Acute myeloblastic leukemia (AML) is characterized by an increased number of immature myeloid cells in bone marrow, which results in hematopoietic insufficiency. Despite improvements in chemotherapy and supportive care measures, the death rate among patients younger than 65 is still 60% 1 . Patients with AML present diverse clinical features, genetic abnormalities, variable response to treatment and heterogeneous prognosis 2 . A number of clinical and biological features are used to predict clinical outcome. Cytogenetics of blast cells is the most important biological characteristic used to identify AML patients with a different response to treatment. There is a general agreement to subclassify AML into three broad prognostic subgroups based on cytogenetical findings: favorable, intermediate, and poor 1, 2 . However it should be noted that there is some controversy regarding the prognostic significance of some cytogenetic abnormalities [3] [4] [5] [6] . Treatment choice is relatively well defined for cases in the favorable and poor-risk categories. However, for patients in the intermediaterisk category, accounting for over half the cases of this disease, the most appropriate treatment is controversial 2,7-10 . As a reflection of this, treatment varies among centers with some advocating chemotherapy while others recommend autologous or even allogeneic stem cell transplantation 2,7-10 . These facts make necessary a better prognostic stratification of Recently, gene-expression profiling has shown to be a promising tool for providing For personal use only. by on April 17, 2008. www.bloodjournal.org From prognostic information in AML beyond that obtained with conventional methods 13, 14 , although this approach has financial and technical limitations. Moreover, gene-expression profiling detects the quantity of mRNA, but not qualitative differences of mRNA that may lead to a different functional role of the protein 15, 16 .
Constitutive genetic characteristics of the patient may play an important role in the prognosis, yet this has scarcely been investigated in AML. In this regard, it is well recognized that most drugs exhibit wide inter-patient variability in their efficacy and toxicity 17, 18 . For many drugs, such differences are due in part to polymorphisms in genes encoding drug metabolizing enzymes (e.g. CYPs, CDA, GSTT1 and SULT1C2), drug transport proteins (e.g. MDR1, MRP2 and MRP3), and genes that recognize and repair DNA lesions 14 (e.g. XPA, XPG, and XPD).
These polymorphisms represent common variations in a DNA sequence that may lead to either reduced or increased activity of the encoded gene 18 . The most frequent type of polymorphisms is the so-called single nucleotide polymorphism (SNP), which accounts for over 90% of genetic variation in the human genome 19 . In solid tumors and in acute lymphoblastic leukemia of children, it has been demonstrated that germ-line SNP impacts on the effects of anticancer drug 20-26 . These aspects have not been fully investigated in adult patients with AML 27,28 . The goal of this study was to identify among 110 adults with intermediate-risk AML SNP in key genes influencing response to chemotherapy, in order to better stratify this poorly defined prognostic AML category. Candidate genes (summarized in table 1) exhibited polymorphisms and encoded proteins that were involved in the pharmacokinetics or pharmacodynamics of antileukemic agents. Priority was given to polymorphisms associated with phenotypes in both clinical and preclinical studies and to those located in exons or in region UTR5' or UTR3', to those with a frequency higher than 10% in the general population, and to those validated. Most of the drugs used for treatment of For personal use only. by on April 17, 2008. www.bloodjournal.org From patients with AML (e.g. idarubicin, cytarabine, mitoxantrone, and etoposide) are substrates for cytochrome P450, which is activated by SXR, and are extruded by p-glycoprotein (MDR1).
The parent drugs or metabolites of idarubicin and etoposide are substrates for glutathione Stransferases (GSTT1 and SULT1C2). The mechanism of action of most of these drugs is damaging DNA of leukemic cells, or by inhibiting topoisomerase IIa (TOPIIa). DNA lesions are repaired by enzimes of nucleotide excision repair family (XPA, XPD, XPG, and ERCC1).
Moreover, cytarabine, a key drug in the treatment of AML, is metabolized by cytidine deaminase (CDA).
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METHODS

Patient selection
Subjects included in this analysis were selected from a group of adult patients with primary AML who were enrolled and treated in 12 Spanish institutions on the prospective trial CETLAM-99. This study was opened for accrual in November 1998 and was closed in July 2003. The corresponding Institutional Review Boards approved the study and all patients signed an informed consent prior to enter into the study. Inclusion criteria were as follows: (i) age between 18 and 60 years, (ii) diagnosis of AML according to the FAB classification, (iii) no history of myelodysplasia or previous cytotoxic drugs or radiation, and (iv) absence of severe concomitant disease. Patients with acute promyelocytic leukemia were excluded and treated in a separate trial. A total of 326 consecutive patients were registered. In short, induction chemotherapy consisted of idarubicin 12 mg/m 2 iv (days 1, 3, 5), cytarabine 500 mg/m 2 /12h iv (days 1, 3, 5, 7) and VP-16 100 mg/m 2 iv (days 1, 2, 3); intensification included cytarabine 500 mg/m 2 /12h iv (days 1-6) and mitoxantrone 12 mg/m 2 iv (days 4-6).
Subsequent treatment was as follows: patients showing the cytogenetic abnormality inversion 16, t(16;16), or t(8;21) received cytarabine 3 g/m 2 /12h iv (days 1, 3, 5); those with a normal karyotype were allocated for autologous peripheral blood transplantation. Finally, those patients with normal cytogenetics and requiring only 1 cycle of induction chemotherapy to achieve complete remission were assigned to receive an autologous peripheral blood transplantation as post-remission strategy. The remaining patients (i.e., patients with cytogenetic abnormalities different from t(8;21) or inv(16), those without valuable mitoses, or those with normal karyotype AML requiring two cycles to achieve complete remission), were allocated to allo-SCT or autologous transplantation according to HLA-identical sibling donor availability. Of the 326 patients included in the study, 182 were in the intermediate-risk group, as defined in the MRC AML 10 trial 5 
Response criteria
Complete remission was defined as the presence of <5% of blast cells in a bone marrow smear after the first or second course of induction therapy. Patients with less than a 50% reduction in marrow leukemia cells after the first course, and those who did not achieve a complete remission after two courses, were considered as refractory and withdrawn from the study. Disease-free survival was defined as the time from complete remission to relapse or death. Overall survival was calculated from diagnosis to death from any cause and risk of relapse was measured from complete emission to relapse censoring deaths in complete remission.
Genotyping
DNA was extracted from patients' peripheral blood and primers and probes were obtained from Applied Biosystems, Foster City, CA (AB) assays on demand-SNP Genotyping product.
The characteristics of the probes used to detect the SNP, according to the supplier's information, are shown in table 3. Probes were synthesized with reporter dye FAM or VIC covalently linked at the 5' end and a quencher dye MGB linked to the 3' end of the probe.
PCR allelic discrimination
SNP analysis was performed using a real-time PCR allelic discrimination TaqMan assay (AB) with minor modifications. All PCR reactions were run in duplicate and contained 100 ng of patient DNA, 12.5 µl TaqMan Universal Master Mix (AB), 1.2 µl primers and probes, and water for a final volume of 25 µl. Appropriate negative controls were also run. Real-time PCR was performed on an ABI Prism 7500 Sequence Detection System (AB) using the following conditions: 50º C for 2 minutes, 95ºC for 10 minutes, and 40 cycles of amplification (95ºC for 15 seconds and 60ºC for 1 minute). For each cycle, the software determined the fluorescent signal from the VIC or FAM-labeled probe. Serial dilution of a specific SNP-DNA into water revealed a detection limit between 0.1-0.01%.
RNA extraction and cDNA synthesis
Blood samples for RNA expression analysis were collected in a K3/EDTA containing tube.
After standard erythrocyte lyses, RNA was isolated using RNeasy Blood Mini Kit (Qiagen) according to the manufacturer's protocol. The concentration, purity, and amount of total RNA were determined by UV spectrophotometry, and the integrity and quality of RNA were assessed by electrophoresis on 1% agarose gel. RNA from samples was quantified in triplicate 
Primers and probes for mRNA expression
For personal use only. by on April 17, 2008. www.bloodjournal.org From AB supplied primers and probes, with the assistance of the assay-on-demand gene expression system (Applied Biosystems). Probes were labeled at the 5' end with the reporter dye molecule FAM. According to the supplier, the primers and probes were designed for the following regions: GUSb gene probe, labeled at the 5' end with the reporter dye molecule FAM (AB), was used as housekeeping gene.
Gene expression and quantification with RT-QPCR
RT-QPCR was performed in a total volume of 20 µl in the ABI Prism 7700 Sequence Detection System (AB, Foster City. CA). All samples for each gene were run in duplicate for 40 cycles using the following master mix: 10 µl of the TaqMan universal PCR master mix, 1 µl of the primers and probes, 3 µl of the cDNA and 6 µl of the Rnase-free water. Thermal cycler conditions were: two minutes 50ºC, 10 minutes 95ºC, 15 sec 95ºC and 1 minutes 60ºC.
Genomic DNA was used as negative control in each run. Fluorescent emission data were captured, and mRNA concentrations were quantified by using the critical threshold value and the curve standard method and quantitative normalization of cDNA in each sample was performed using the expression of total RNA concentration as an internal control 27 .
Statistical analysis
Descriptive statistical analysis of the main characteristics of the patients was performed.
Differences between groups were measured by Fisher's exact test or the Kruskal-Wallis test.
Survival probabilities were estimated using the Kaplan-Meier method. Survival curves were compared by the log-rank test, and the Cox proportional hazards model was used to estimate the risk ratio of events after controlling for prognostic variables. We considered the following characteristics: age (<50 years vs. >50), WBC count (<20x10 9 /l vs. >20x10 9 /l), FAB group, 
RESULTS
Patients, overall response to treatment, and follow-up characteristics
A total of 110 patients, consisting of 66 men (60%) and 44 women (40%) with a median age of 44 years (range: 16-60), were evaluable for response. Of these, 86 (78%) achieved a complete remission, 11 (10%) were chemo-resistant and 13 (12%) died during induction.
Actuarial probability of relapse was 58% (95% CI: 44%-72%). After a median follow up of the whole series of 12 months (range 3-64), overall survival was 47% (95%CI: 37%-57%) at 2 years. Characteristics of this group of patients did not differ from those patients (n=72) with intermediate-risk AML included in the CETLAM-99 study and not included in this analysis (table 2) .
Allele frequencies
Genotype frequencies in the group of 110 patients were comparable to those found in a healthy Caucasian population (table 4) . No associations were found between genotype and age, sex, or other prognostic variables (data not shown).
Association between genetic polymorphisms and induction failure
The variant UTR 5' genotype -4A>G of the DNA repair gene XPA was associated with chemo-resistant disease. Individuals with the wild-type genotype (AA) of XPA had a probability of resistant disease of 6.5%; those with heterozygous genotype (AG) of 11%, and patients with the homozygous variant genotype (GG) had a probability of refractoriness to chemotherapy of 30%. Fisher exact test (two-tailed) of GG cases versus the rest of the patients was marginally significant (p=0.07). In the multivariate model, XPA GG genotype was the only independent factor increasing the risk of resistant disease (RR=14; p=0.02) (tables 5 and 6). Fifty percent of patients with XPA GG genotype were either chemo-resistant or died during the induction, as compared to 22% for the rest of the patients (p=0.053). No single factor was found to be associated with induction mortality.
Association between genetic polymorphisms and relapse rate
Variant form in UTR 3' genotype Ex29-193C>T of MDR1 gene was significantly associated with relapse rate. Actuarial probability of relapse was 45% for individuals wild-type (TT), and 84% for individuals with the variant genotype (CT or CC) (log-rank test, p=0.02). In the multivariate analysis only molecular factors were found to be predictive for relapse: 
Association between genetic polymorphisms and overall survival
Consistent with the above-mentioned association of XPA -4A>G variant alleles and chemoresistance, overall survival for patients with AA, AG, and GG alleles of XPA gene was 49%, 29%, and 0%, respectively (log rank test, p=0.1). We determined the influence of XPA gene polymorphism on overall survival with a Cox regression model. The most important factor influencing survival was XPA GG genotype (RR 3.4; p=0.02). Other factors associated with overall survival in the multivariate analysis were WBC counts and variant alleles of MDR1 gene (figures 1 and 2) (tables 5 and 6).
Association between genetic polymorphisms and clinical outcome in the group of patients with normal cytogenetics.
When we restricted the univariate analysis to the group of patients with normal cytogenetics (n=70), we found identical prognostic factors as to those identified in the whole series of 110 patients ( Table 5 ). In the multivariate analysis for overall survival, WBC (RR 2.6; p=0.0001)
For personal use only. by on April 17, 2008. www.bloodjournal.org From and homozygous XPA (RR 4; p=0.02) were independent prognostic factors, while in the multivariate analysis for chemo-resistance only homozygous XPA (RR 66; p=0.01) was found to have a statistical significance ( Table 6 ).
Relationship of gene polymorphisms and cDNA expression
We analyzed the relationship of gene polymorphisms and cDNA expression of the three genes (XPA, MDR and SULT1C2) found to be associated with clinical outcome. In one of these, XPA, polymorphism was located in the promoter area. We hypothesized that the SNP in XPA modified mRNA expression of the gene. For this reason, XPA UTR 5' -4A>G polymorphism and cDNA expression was assessed in 37 healthy volunteer blood donors from the geographical area of Barcelona. Of them, 15 (35%) had a wild-type genotype, 14 (50%) were heterozygous, and 6 (15%) were homozygous for the variant genotype XPA (-4A>G). We found a close association between XPA alleles and mRNA XPA expression. Thus, individuals with XPA GG genotype demonstrated much lower XPA expression levels as compared with AA and AG genotypes (p=0.00001; figure 3 ). Polymorphisms of MDR1 and of SULT1C2 are located at 3'UTR and in exonic area, respectively. As expected, there was no association of SNP in these locations with mRNA expression (data not shown).
DISCUSSION
We investigated for an association of polymorphisms of 11 genes with clinical outcome in 110 patients with intermediate-risk AML. Polymorphisms from 4 genes showed no association with outcome (SXR, GSTT1, ERCC5 and CDA), whereas polymorphisms of 7 genes ( Table 5 ) showed in the univariate analysis an association with induction failure (ERCC1 and XPA), relapse (XPD, MRD1, TOP2A, SULT1C2, and VEGF) and overall survival (XPD, XPA and MRD1). Polymorphisms of 3 genes were independent prognostic factors in the multivariate analysis: XPA for chemo-resistance and overall survival, MDR1 for relapse and overall survival, and SULT1C2 for relapse ( Table 6 ).
One of the most striking findings in this work was the association of polymorphisms in the Because DNA repair enzymes are correctives for DNA damage induced by anticancer agents, it was hypothesized that polymorphisms in DNA repair genes might influence treatment outcome of neoplasm 23 . We have observed, for the first time, an association of XPA genotype and outcome of therapy for AML, in which individuals with the genotype XPA -4A>G GG had an inferior outcome, largely caused by an increase in chemo-resistant cases. Moreover, findings in this study suggest an allele dosage effect of XPA A>G with respect to outcome.
Thus, the proportion of individuals with resistant disease was of 6.5% for XPA AA, of 11% for those AG, and of 30% for patients with the GG genotype. Consistent with this, actuarial For personal use only. by on April 17, 2008. www.bloodjournal.org From probability of overall survival at 5 years was of 50% for XPA AA, 29% for AG, and 0% for GG. In the multivariate analysis, adjusted for the most important clinical and biological characteristics, XPA GG genotype was the most important factor associated with chemoresistance and with overall survival. This association of XPA GG genotype and clinical outcome might be due to changes in the functional capacity of the protein to repair DNA 31 . In this sense, it is of note that XPA -4A>G polymorphism is located in the promoter area, which might affect its translation efficiency. Indeed, we found a strong correlation between XPA -4A>G polymorphism and quantity of mRNA expression, healthy controls with XPA GG genotype having the lowest XPA mRNA expression ( figure 2 ). This is an intriguing finding, since it has been considered that a higher, and not the opposite, efficient DNA repair system might lead to a lower efficacy of chemotherapy 33 . However, recent data seems to support that also reduced DNA repair capacity might lead to resistance to chemotherapy, by interrupting cell signals to undergo to apoptosis. Thus, chemo-resistance in solid tumors has been associated with enhanced expression of XPA in some 33 but not in all studies 34, 35 , and it has been recently reported that reduced mismatch repair efficiency may cause resistance to cytotoxic drugs, by an inability to detect DNA damage, thus preventing cells to undergo DNA damage-induced apoptosis [36] [37] [38] [39] [40] . Moreover, in hematological malignancies, Allan et al. have recently reported that a polymorphism in XPD that protects against cell death is associated with poorer prognosis in AML patients 27 . Further support of the notion that DNA repair and apoptosis are functionally linked comes from the experiment in which p53-dependent apoptosis is compromised in fibroblasts from patients with XPD variant alleles, a phenotype that can be restored by expression of XPD wild-type 41 . Alternatively, the association of XPA variants and poorer outcome might be explained by the fact that inefficient DNA repair leads to additional instability and more aggressive tumors [42] [43] [44] [45] [46] . In the present study the relationship between polymorphisms in MDR1, the most studied gene concerning protection of host cells from toxics, and relapse rate and overall survival in intermediate-risk AML is also of note. We have observed that polymorphisms in UTR 3' of the MDR1 gene (Ex29-193C>T) were associated with increased relapse rate (45% for individuals wild-type, and 84% for individuals with the variant genotype) and poorer overall survival (37% for individuals wild-type, and 14% for individuals with the variant genotype).
Similarly to the results herein presented, Illmer et al. reported that MDR1 gene polymorphisms in exons 12, 21 and 26 affected therapy outcome in AML patients 28 . In that study, those polymorphisms associated with poor survival had the lowest median of MDR1 mRNA expression. It has been also observed a significant correlation of polymorphisms in MDR with both increased levels and function of the protein 47,48 . We did not perform immunophenotypic analysis to exclude a higher MDR protein expression on blast cells, but we found no correlation between alleles and MDR expression at mRNA level. The influence of MDR1 protein in the response to chemotherapy is widely known, since MDR1 mutation is frequently acquired in many tumor types following cytotoxic chemotherapy and confers chemo-resistance through gene amplification 24 . The results herein presented, and those of Illmer et al 28 , support that the role of MDR1 on response to treatment of AML is not exclusively due to acquired mutations, but also to constitutional polymorphisms.
Another constitutive genetic finding that was associated with response to the treatment in our study was the homozygosity of SULT1C2 for the polymorphism Asp5Glu. SULT1C2 is a gluthatione sulfur transferase (GST), an enzyme that adds sulfur molecules to a wide range of acceptor molecules 49 and that plays an important role in determining the cytotoxicity of chemotherapeutical drugs, including anthracyclines 50 , a key drug in the treatment of AML patients. Thus, recent reports support the idea that reduced GST activity is associated with toxic deaths 51 whereas increased GST activity is associated with a higher incidence of relapse 52 . We found no effect of SULT1C2 Asp5Glu genotype on overall survival but did demonstrate a higher relapse rate (figure 2a) and reduced disease-free survival (figure 2b) in patients with SULT1C2-homozygous (CC and GG) genotype, suggesting a more efficient activity of this genotype. We tried to find an explanation for the relationship between SULTIC2 heterozygosis and reduced probability of relapse. It has been shown that heterozygosis may lead to a different functional capacity of the encoded protein and to a different mRNA expression 28 . The first possibility cannot be ruled out since we did not perform functional studies. With respect to the second, we found no association of SULT1C2 genotype and mRNA expression.
Finally, although the precise functional mechanism of the effect of polymorphisms of XPA, MDR1, and SULT1C2 in AML therapy remains to be determined, the findings herein presented strongly support the importance of considering these genomic polymorphisms as prognostic markers in intermediate-risk AML.
Gene Function Reference
Drug Metabolic Pathway
CDA
The enzyme cytidine deaminase catalyzes the hydrolytic deamination of cytidine or deoxycytidine to uridine or deoxyuridine, respectively.
SXR
The human nuclear pregnane X receptor (PXR) activates cytochrome P450-3A expression in response to a wide variety of xenobiotics and plays a critical role in mediating drug-drug interactions 50 GSTT1 Glutathione S-transferase (GST) theta 1 (GSTT1) is a member of a superfamily of proteins that catalyze the conjugation of reduced glutathione to a variety of electrophilic and hydrophobic compounds.
SULT1C2
Sulfotransferase enzymes catalyze the sulfate conjugation of many hormones, neurotransmitters, drugs, and xenobiotic compounds.
24-26
Multidrug Resistance TR
MDR1
This protein is a member of the MDR/TAP subfamily. Members of the MDR/TAP subfamily are involved in multidrug resistance. It is responsible for decreased drug accumulation in multidrug-resistant cells and often mediates the development of resistance to anticancer drugs.
28,48
Angiogenesis VEGF Vascular endothelial growth factor (VEGF), a major mediator of vascular permeability and angiogenesis, may play a pivotal role in mediating the development and progression of cancer.
53
DNA Repair
XPD
The nucleotide excision repair pathway is a mechanism to repair damage to DNA. The protein encoded by this gene is involved in transcription-coupled nucleotide excision repair and is an integral member of the basal transcription factor BTF2/TFIIH complex. The gene product has ATP-dependent DNA helicase activity and belongs to the RAD3/XPD subfamily of helicases.
19, 23
XPA It is involved in damage recognition after XPC/hHR23B.
19, 33-35
ERCC1 and ERCC5 ERCC1 and ERCC5 are two structure specific endonucleases, incise on the 5' and 3' sites of the DNA adduct,
Respectively, to remove the 24-32 base oligonucleotides that contain the lesion.
TOP2A This nuclear enzyme is involved in processes such as chromosome condensation, chromatid separation, and relief of torsional stress that occurs during DNA transcription and replication. 1 (1.1-4.1)  2.1 (1.1-4.1 
54
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